What Happened?
Shares of vaccine biotechnology company Novavax (NASDAQ: NVAX) jumped 11.3% in the afternoon session after documents revealed that advisers to the U.S. Food and Drug Administration (FDA) will weigh updating the 2026-27 COVID-19 vaccines to target the latest circulating XFG subvariant.
An FDA advisory panel is set to vote on the updated formulation for the next immunization campaign. This development comes as vaccine manufacturers indicated they were prepared to produce a vaccine targeting the XFG strain.
For Novavax, this potential update points to continued demand for COVID-19 vaccines, representing an opportunity for future sales if the new formulation is approved by regulators.
Is now the time to buy Novavax? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Novavax’s shares are extremely volatile and have had 42 moves greater than 5% over the last year. But moves this big are rare even for Novavax and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 13 days ago when the stock dropped 2.8% on the news that the April PPI report showed wholesale inflation accelerating to 6% annually, with service-sector prices rising at their fastest pace in four years.
Healthcare companies, drug makers, hospitals, and insurers, earn revenue from clinical services and product sales. While the sector is traditionally defensive, the hot PPI print creates a two-pronged headwind.
First, rising service-sector inflation (up 1.2% monthly) increases the operating costs for hospital systems and providers. Second, as inflation becomes a dominant political issue, drug companies' visible price-setting power makes them a primary target for regulatory intervention.
Novavax is up 45.8% since the beginning of the year, and at $10.40 per share, it is trading close to its 52-week high of $11.19 from February 2026. Despite the year-to-date gain, investors who bought $1,000 worth of Novavax’s shares 5 years ago would now be looking at only $68.89.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
